Trials / Completed
CompletedNCT03208465
Empagliflozin Versus Sitagliptin Therapy for Improvement of Myocardial Perfusion Reserve in Diabetic Patients With Coronary Artery Disease
Empagliflozin Versus Sitagliptin Therapy for Improvement of Myocardial Perfusion Reserve in Diabetic Patients With Coronary Artery disease_ELITE Trial
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 100 (actual)
- Sponsor
- CHEOL WHAN LEE, M.D., Ph.D · Academic / Other
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
This trial evaluates the effects of Empagliflozin versus Sitagliptin, in addition to standard of care, on global myocardial perfusion reserve using dynamic single-photon emission computed tomography (SPECT) images.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Empagliflozin | In empagliflozin group, patients will be prescribed empagliflozin 10mg/day. |
| DRUG | Sitagliptin | In sitagliptin group, patients will be prescribed sitagliptin 100mg/day. |
Timeline
- Start date
- 2017-08-07
- Primary completion
- 2019-08-01
- Completion
- 2019-08-01
- First posted
- 2017-07-05
- Last updated
- 2019-08-07
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT03208465. Inclusion in this directory is not an endorsement.